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Summary
 
CD8
 
1
 
 cytotoxic T lymphocytes (CTLs) have the ability to recognize and eliminate virally in-
fected cells before new virions are produced within that cell. Therefore, a rapid and vigorous
CD8
 
1
 
 CTL response, induced by vaccination, can, in principle, prevent disseminated infection
in vaccinated individuals who are exposed to the relevant virus. There has thus been interest in
novel vaccine strategies that will enhance the induction of CD8
 
1
 
 CTLs. In this study, we have
tested the hypothesis that targeting an antigen to undergo more efficient processing by the class
I processing pathway will elicit a more vigorous CD8
 
1
 
 CTL response against that antigen. Tar-
geting a type I transmembrane protein, the HIV-1 envelope (env) protein, for expression in the
cytoplasm, rather than allowing its normal co-translational translocation into the endoplasmic
reticulum, sensitized target cells expressing this mutant more rapidly for lysis by an env-specific
CTL clone. Additionally, a greatly enhanced de novo env-specific CTL response was induced
in vivo after immunization of mice with recombinant vaccinia vectors expressing the cytoplas-
mic env mutant. Similarly, targeting a cytoplasmic protein, HIV-1 nef, to undergo rapid cyto-
plasmic degradation induced a greatly enhanced de novo nef-specific CD8
 
1
 
 CTL response in
vivo after immunization of mice with either recombinant vaccinia vectors or DNA expression
plasmids expressing the degradation targeted nef mutant. The targeting of viral antigens for
rapid cytoplasmic degradation represents a novel and highly effective vaccine strategy for the
induction of enhanced de novo CTL responses in vivo.
 
C
 
D8
 
1
 
 CTLs play a vital role in controlling the spread
of viral infection (1–3). These cells have the ability to
recognize virally infected cells that present peptide epitopes
derived from viral proteins on their surfaces. These viral
peptides are presented by the MHC class I molecules syn-
thesized within the infected cells. The processing of viral
proteins for association with class I molecules can occur as
soon as viral proteins are translated (4, 5), and is not depen-
dent upon any subsequent events in the life cycle of the vi-
rus. Thus, the peptide epitopes may be presented to and
recognized by CD8
 
1
 
 CTLs before the viral life cycle is
complete, conferring on these CTLs the ability to lyse vi-
rally infected cells before new virions are produced (6).
In HIV-1 infection, the ability of CTLs to recognize and
lyse infected cells may be responsible for the dramatic fall in
viremia after acute infection, a fall that occurs concomi-
tantly with a rise in HIV-specific CTL activity (7–12). Fur-
thermore, the control of viral replication seen during the
prolonged clinically latent stage of the infection has been
associated with HIV-specific CTL activity (13). It is possi-
ble that if this CTL activity could be enhanced, the total
elimination of viral burden could be achieved. In a vaccine
setting, the rapid clearance of the initially infected cells by
vaccine-induced CTLs could, in principle, result in steriliz-
ing immunity, and would prevent clinical manifestations of
the infection. In studies of the immune response to the
lymphocytic choriomeningitis virus, a virus that is capable
of establishing a persistent infection of mice, it has been
shown that a CD8
 
1
 
 CTL response specific for LCMV anti-
gens is able to clear the persistent infection, or if induced by
vaccination, to prevent the establishment of a persistent in-
fection (14–16). Indeed, it has been observed that there is a
detectable HIV-specific CTL response in HIV-uninfected
sexual contacts of HIV-infected individuals suggesting that
a strong CTL response against HIV may confer protection
from natural infection (17, 18).
There is now considerable interest in the development
of vaccine strategies that will enhance the generation of vi-
rus-specific CTL responses (9, 19). One potential approach
to inducing a more vigorous CTL response involves spe-
cific targeting of vaccine antigens into the MHC class I an-
tigen processing pathway. Normally, cytoplasmic degrada-
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tion of a small fraction of the viral protein made in an
infected cell provides the peptide substrates that enter the
class I pathway. Cytoplasmic proteins are degraded by the
ubiquitin (Ub)
 
1
 
-dependent pathway through the action of
proteasomes (6, 20–24) and the resulting peptides are then
transported by the Tap1/Tap2 heterodimer (25–32), into
the endoplasmic reticulum where they associate with MHC
class I molecules and 
 
b
 
2
 
-microglobulin. The resulting com-
plexes are then transported via the exocytic pathway to the cell
surface where they are recognized by CD8
 
1
 
 CTLs (6, 33).
Several lines of evidence suggest that an APC expressing
higher concentrations of MHC class I molecules loaded with
the appropriate peptide from a given antigen will stimulate
a more vigorous CD8
 
1
 
 CTL response against the relevant
antigen (34–36). Given that cytoplasmic degradation of an-
tigens by the 26S proteasome provides the peptide substrate
for the class I pathway (21, 37, 38), targeting of vaccine an-
tigens to undergo more efficient degradation in the cyto-
plasm should yield increased amounts of peptide substrate
available to enter the class I pathway. Increased production
of peptide substrate should result in a higher concentration
of cell surface MHC class I molecules that are loaded with
peptides derived from the relevant antigen. Enhancing the
entry of viral proteins into the class I pathway may be ac-
complished by either targeting a noncytoplasmic protein to
the cytoplasm for degradation or by targeting a cytoplasmic
protein for more rapid degradation.
The factors that regulate the degradation of cytoplasmic
proteins by the 26S proteasome have been well described.
Unlike the 20S proteasome, which recognizes unfolded
proteins, the 26S proteasome can recognize proteins in a
folded state, particularly proteins that have been modified
by the conjugation of a polyubiquitin chain through an
isoamide bond to a conformationally free Lys residue (39).
It is the presence of this polyubiquitin chain that is recog-
nized by the proteasome and targets the substrate for degra-
dation. In addition to the conjugation of ubiquitin, the
degradation is also regulated by the substrate protein itself.
It has been shown that the NH
 
2
 
-terminal amino acid of the
substrate protein is responsible for determining the rate of
conjugation of the polyubiquitin chain, and thus, the tar-
geting of the protein for degradation by the proteasome
(40, 41).
As was initially demonstrated in 
 
Saccharomyces cerevisiae
 
and later by the work of Townsend et al. in mammalian
cells (42), the degradation of proteins with NH
 
2
 
-terminal
residues other than Met can be studied by expressing in
cells fusion constructs in which the coding sequence of the
substrate protein is fused in frame to the COOH-terminal
end of the coding sequence of Ub. Ub is normally made in
the cell as a polyprotein chain that is cleaved by Ub hydro-
lases at the COOH terminus of each Ub subunit, giving
rise to individual Ub molecules (43). These same hydro-
lases will also cleave the Ub–substrate fusion protein at the
COOH terminus of Ub, exposing the NH
 
2
 
 terminus of the
substrate. In these constructs, the NH
 
2
 
 terminus of the sub-
strate may be mutated to residues other than Met. By ex-
pressing such fusion proteins in 
 
S. cerevisiae
 
, Bachmair et al.
showed that the identity of the NH
 
2
 
 terminal amino acid
residue had a dramatic effect on the degradation rate of the
substrate protein (44). When the substrate protein had a
Met NH
 
2
 
 terminus, the half-life was 
 
.
 
10 h; however, if
the NH
 
2
 
 terminus was Arg, the half-life of the substrate was
 
,
 
2 min. Townsend et al. then showed that this strategy
could be used to overcome a class I processing defect ob-
served late in the course of vaccinia infection (42). They
generated a fusion of Ub to influenza nucleoprotein (NP)
and showed that if the NH
 
2
 
 terminus was an Arg, the pro-
tein was processed and presented to CD8
 
1
 
 CTLs, whereas
NP with a Met NH
 
2
 
 terminus was not processed and pre-
sented. More recently, Grant et al. demonstrated that the
rate of presentation of an endogenous antigen corresponded
directly to its rate of degradation via the Ub-mediated
pathway, and that the expression of degradation targeted
forms of antigen resulted in a more rapid processing of the
antigen for presentation by MHC class I (36). Whether the
rapid degradation of endogenous antigens affects immuno-
genicity in vivo is unclear.
In this report, we have analyzed two different approaches
for inducing the cytoplasmic degradation of vaccine anti-
gens in an effort to enhance the generation of CTLs, and
have examined whether the degradation targeted antigens
can induce enhanced primary CTL responses in the vaccine
setting. In the first approach, we used a form of the HIV-1
env protein that lacks the signal sequence and is therefore
expressed and degraded entirely in the cytoplasm. The sec-
ond approach involved the generation of Ub fusion con-
structs in which the Ub coding sequence was fused to the
NH
 
2
 
 terminus of mutant forms of the HIV-1 nef protein.
In both cases, enhanced cytoplasmic degradation of the vac-
cine antigen was observed and was associated with mark-
edly enhanced stimulation of murine and human CTLs and
enhanced generation of de novo murine CTL responses in
vivo.
 
Materials and Methods
 
Generation of Ub-nef Fusion Constructs.
 
The full-length Ub gene
was amplified from genomic DNA by PCR using the following
primer pair: 5
 
9
 
 primer: GTCAGTCAGTCAGTCAACTAGTAT-
GCAGATCTTCGTGAAGACC, 3
 
9
 
 primer: TTTTGA CCACT-
TGCCACC (CAT or CCT)ACCCCCCCTCAAGCGCAGGAC.
The 5
 
9
 
 primer contains a SpeI site for cloning and the 3
 
9
 
 primer
contains the reverse compliment of the 5
 
9
 
 end of the HIV-1 nef
gene with either a Met or Arg codon at the NH
 
2
 
 terminus. A 50-
fold excess of 5
 
9
 
 primer was used to generate a single stranded
PCR product. The resulting 271 base product was gel purified
from the double stranded PCR product and used as the 5
 
9
 
 primer
for the amplification of HIV-1 nef from the plasmid pNL4-3.
The 3
 
9
 
 primer for amplifying nef, GTCAGTCAGTCAGTC-
ACTTAAGTCAGCAGTTCTTGAAGTACTC, contained an AflII
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
-gal, 
 
b
 
-galactosidase; env, envelope; HA,
hemagglutinin; MOI, multiplicity of infection; NP, nucleoprotein; O/N,
overnight; SIV, simian immunodeficiency virus; ss
 
2
 
, signal sequence mi-
nus; Ub, ubiquitin; vac, vaccinia; wt, wild type. 
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site. The resulting 894-bp Ub-nef fusion product was gel purified
and subcloned into the pCRScript vector (Stratagene Corp., La
Jolla, CA).
 
Generation of Recombinant Vaccinia Viral Vectors.
 
The Ub-nef fusion
gene was cut out of pCRScript and cloned into the pSC11.MCS1
vector using SpeI and AflII sites for the generation of recombinant
vaccinia vectors expressing the Ub-nef fusion protein. The recom-
binant viral vectors were created by infecting CV-1 cells with wild-
type (wt) vaccinia virus (vWR-Lvar), followed by co-transfection
of the infected cells with 4.4 
 
m
 
g pSC11.MCS1 constructs using
the CellPhect transfection kit (Pharmacia LKB Biotechnology Inc.,
Piscataway, NJ). Recombinant virus was screened by the expres-
sion of 
 
b
 
-galactosidase (
 
b
 
-gal) and selected by resistance to BrdU.
The recombinant viruses were carried through three rounds of
plaque purification under selective conditions. Expression of the
foreign gene was then assayed by Western blot analysis.
 
Generation of In Vivo Expression Constructs.
 
The Ub-nef fusion
gene was cut out of the pSC11 vector using NotI and BamHI,
and cloned into the pcDNA3 vector (Invitrogen, San Diego,
CA). The nef gene was cut out of pCRScript using NotI and
SmaI and cloned into the NotI and EcoRV sites in the pcDNA3
vector. Expression by these constructs was checked by Western
blot analysis of transiently transfected HeLa cells and CT26 cells.
 
Cell Lines.
 
CT26nef cells were generated by transfecting the
CT26 tumor line with the pcDNA3nef construct using the mam-
malian transfection kit (Stratagene Corp.). Stable transfectants
were selected by neomycin resistance and maintained in 400 
 
m
 
g/ml
G418. Expression of nef in stable transfectants was checked by West-
ern blot analysis.
 
Pulse-Chase Metabolic Labeling.
 
5 
 
3
 
 10
 
6
 
 human EBV–trans-
formed B cells (B-lymphoblastoid cell line [B-LCL]) per time point
were infected with recombinant vaccinia vectors expressing ei-
ther 
 
b
 
-gal (vSC8 control), nef, UbMNef, or UbRNef for 2 h at a
multiplicity of infection (MOI) of five. Cells were then washed
and incubated for 1 h in Met-free, Cys-free RPMI containing 5%
dialyzed FCS and antibiotics. 100 
 
m
 
Ci [
 
35
 
S]Cys and 100 
 
m
 
Ci
[
 
35
 
S]Met were added to the cultures and incubated for 30 min. Cells
were washed once with PBS and then incubated in RPMI con-
taining 10% FCS, antibiotics, and 10
 
3
 
 Met, 10
 
3
 
 Cys for 0, 15,
60, or 240 min. After incubation, cells were washed once in PBS
and then pelleted.
 
Immunoprecipitation of Labeled Cells.
 
Cell pellets were resus-
pended in 1 ml lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100) 
 
1
 
 protease inhibitors and incu-
bated for 30 min at 4
 
8
 
C. Cell debris was pelleted at maximum
speed for 15 min at 4
 
8
 
C. Supernatants were transferred to fresh
tubes and precleared two times with normal rabbit serum and
protein G–Sepharose beads (once overnight [O/N] at 4
 
8
 
C, once
for 2 h at 4
 
8
 
C). Nef proteins were immunoprecipitated with anti–
Nef-COOH-terminal polyclonal sera (National Institutes of Health
AIDS Research and Reference Reagent Program, Rockville,
MD) at 1:250 dilution for 1 h. Immune complexes were collected
on protein G–Sepharose beads for 1 h and the supernatant was as-
pirated. Protein G–Sepharose beads were washed two times in ly-
sis buffer 
 
1
 
 1% SDS, four times in lysis buffer 
 
1 
 
1% SDS 
 
1
 
 0.5M
NaCl, and again two times in lysis buffer 
 
1
 
 1% SDS. Immune
complexes were removed from beads by boiling in SDS loading
buffer for 10 min. Radiolabeled proteins were separated by SDS-
PAGE on a 14% gel and visualized by autoradiography.
 
Western Blot Analysis.
 
Cells were infected with recombinant
vaccinia vectors at an MOI of three for 2 h and then incubated
O/N to allow protein expression. Transfected cells were incu-
bated O/N under normal culture conditions. 10
 
6
 
 cells per lane
were pelleted, resuspended, and lysed in SDS sample buffer for 10
min followed by boiling for 10 min. Cell debris was pelleted at
maximum speed for 10 min and proteins were separated by SDS-
PAGE on a 14% minigel. Bands were transferred to nitrocellulose
and the nitrocellulose was blotted according to enhanced chemi-
luminescence kit protocols (1
 
8
 
 Ab anti–Nef-COOH terminus at
1:2,500 dilution, 2
 
8
 
 Ab goat anti–rabbit [Bio Rad Labs., Hercules,
CA] at 1:3,000 dilution).
 
In Vitro Stimulation of Bulk PBMC.
 
Autologous B-LCL were
infected with recombinant vaccinia vectors for 2 h, incubated O/N,
and treated with psoralen and UV irradiation to inactivate vac-
cinia. These cells were then used to stimulate nef-specific CTLs
from bulk PBMCs. PBMCs were isolated from the blood of an
HIV-seropositive donor by Ficoll gradient centrifugation, and
then cultured for 10 d in the presence of IL-2 and titrating num-
bers of stimulating cells.
 
CTL Assay.
 
Target cells expressing Ag or a control Ag are la-
beled with 
 
51
 
Cr for 2 h and then washed three times to remove
excess Cr. Targets are mixed with stimulated effector cells at vary-
ing E/T ratios and incubated for 4 h at 37
 
8
 
C in 200 
 
m
 
l RPMI 
 
1
 
10% FCS supplemented with IL-2 and antibiotics. Plates are spun
to pellet cells and 100 
 
m
 
l media is removed from each well and
counted. Percent specific lysis is defined as ([counts experimental
lysis 
 
2
 
 counts media lysis] / [counts NP40 lysis 
 
2
 
 counts media
lysis]) 
 
3 
 
100%.
 
Generation of Envelope-specific CTL In Vivo by Immunization.
 
Mice were immunized intraperitoneally with either 10
 
7
 
 or 10
 
8
 
PFU of recombinant vaccinia vectors expressing either 
 
b
 
-gal (con-
trol), wild-type envelope (env), or signal sequence minus forms
of the env protein (ss
 
2
 
 env) (gifts of Dr. Patricia Earl, National
Institutes of Health). 3 wk after immunization, the mice were
killed and their spleens were harvested. Splenocytes were isolated
by homogenizing the spleen, and then passing the suspension
through a nylon mesh followed by Ficoll gradient centrifugation.
Splenocytes were then incubated in the presence of IL-2 and ei-
ther the immunodominant H-2 L
 
d
 
 peptide epitope P18, or media
alone for 5 d. Stimulated splenocytes were then used as effectors
in a standard 
 
51
 
Cr release assay for CTL activity.
 
Precursor CTL Frequency Analysis.
 
BALB/c mice were immu-
nized intraperitoneally with 10
 
7
 
 PFU of vaccinia (vac) control,
vac-env, or vac-ss
 
2
 
 env in 0.1 ml sterile PBS. At 21 d after im-
munization, mice were killed and spleens were harvested. Sple-
nocytes were isolated as described above and counted. Titrating
numbers of splenocytes were plated in 96-well plates (48 wells/
dilution) in the presence of 10
 
5
 
 irradiated naive syngeneic spleno-
cytes that had been pulsed with the P18 peptide (50 
 
m
 
M) for 2 h.
These cells were cultured for 7 d in media containing 10% super-
natant from Con A–stimulated rat splenocytes, 50 
 
m
 
M methyl-
 
a
 
-
 
d
 
-mannopyranoside, 10 U/ml IL-2, and 50 
 
m
 
M 2-ME. After
culture, each well was split into two equal volumes and assayed
for CTL activity against 
 
51
 
Cr-labeled, P18- or media-pulsed P815
cells (3,000 targets/well). The natural log of the fraction of nega-
tive cultures was plotted against the number of splenocytes/well.
The frequency of precursor CTLs (f ) was obtained from the slope of
the resulting lines and is given by the formula f 
 
5
 
 (lnb 
 
2
 
 lny) / x
where 
 
b
 
 is the y-intercept for each line, 
 
y
 
 is the fraction of nega-
tive wells, and 
 
x
 
 is the number of splenocytes/well.
 
Stimulation of a Primary env-specific CTL Response.
 
BALB/c mice
were immunized intraperitoneally with 10
 
7
 
 PFU of vac control,
vac-env, or vac-ss
 
2
 
 env in 0.1 ml sterile PBS. At 7 d after immu-
nization, mice were killed and spleens harvested. Splenocytes were
isolated as described earlier. Isolated splenocytes were counted
and used as effectors directly in a 
 
51
 
Cr release assay (as described 
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above) for primary CTL activity. Target cells were MHC class I
matched, MHC class II negative P815 cells that had been pulsed
with the P18 peptide of HIV-1 env or media and labeled with
 
51
 
Cr for 2 h.
 
Generation of nef-specific CTLs In Vivo by Immunization.
 
Two
different immunization protocols were used. Mice were immu-
nized with either 10
 
7
 
 PFU recombinant vaccinia vectors expressing
either 
 
b
 
-gal (control), UbMNef, or UbRNef intraperitoneally, or
they were immunized with 50 
 
mg pcDNA3 expressing no insert,
nef, UbMNef, or UbRNef at four sites intramuscularly. 3 wk af-
ter immunization, the mice were killed and their spleens were
harvested. Splenocytes were isolated by resuspending the spleen,
and passing it through a nylon mesh followed by Ficoll gradient
centrifugation. Splenocytes were then incubated in the presence
of IL-2 and psoralen/UV-treated vVnef-infected CT26 or P815
(MHC matched) stimulator cells for 5 d. Stimulated splenocytes
were then used as effectors in a standard 51Cr release assay for
CTL activity.
Anti-CD8 Blocking of CTL Activity. BALB/c mice were im-
munized with 200 mg pcDNA3 constructs and splenocytes were iso-
lated and stimulated as described above. Stimulated splenocytes were
then preincubated with the anti-CD8 antibody 2.43 (American
Type Culture Collection, Rockville, MD) or an isotype matched
control Ab at 1:250 dilution for 2 h. Splenocytes were then used,
without additional washing, as effectors in a standard 51Cr release
assay for CTL activity.
Results
Enhanced Presentation of a Cytoplasmic Form of the HIV-1
env Protein to env-specific CTLs. To determine whether tar-
geting vaccine antigens for rapid cytoplasmic degradation
enhances the generation of antigen-specific CTLs, we first
examined the effects of targeting the HIV-1 env protein, a
type I transmembrane protein, for synthesis and degrada-
tion in the cytoplasm. Targeting of the env protein into the
cytoplasm was accomplished by expressing in cells an ss2
env. Previous studies have shown that ss2 form of the he-
magglutinin (HA) protein of influenza virus (45) and the
env protein of HIV-1 (46, 47) expressed using vaccinia vec-
tors can be processed for presentation to specific CTLs.
When a ss2 form of the HIV-1 env protein is expressed in
cells using a vaccinia vector (vac-ss2 env), steady state levels
of env are very low or undetectable by Western blot de-
spite the fact that these cells are readily recognized by env-
specific CTLs (46). To determine whether ss2 env protein is
subject to rapid degradation, pulse chase experiments were
carried out as described in Materials and Methods. How-
ever, the protein remained undetectable, even when cells
infected with vac-ss2 env were lysed immediately after 35S-
labeling. Two different sources of pooled polyclonal sera
from HIV seropositive individuals were used in attempts to
immunoprecipitate the ss2 env protein. Under conditions
where a very strong 160-kD band is detected in immuno-
precipitates of cells infected with a vector carrying the
wild-type  env gene, no band in the molecular weight range
expected for the nonglycosylated ss2 env was seen in cells
infected with a vaccinia vector carrying the ss2 env gene
(data not shown). These results suggest that the protein un-
dergoes extremely rapid degradation, resulting in the in-
ability to detect any full-length protein in these cells.
To compare the processing of wt and ss2 forms of the
env protein, we used the env-specific human CD81 CTL
clone A42.46, which recognizes a 9–amino acid env epitope
in association with HLA A3.1 (48). As shown in Fig. 1, this
clone recognized an autologous B-LCL infected with re-
combinant vaccinia virus expressing the HIV-1 env protein
(vac-env). The clone also lysed target cells infected with a
vaccinia vector expressing the vac-ss2 env in a standard
51Cr release assay. However, when target cells were assayed
at 2 h after infection with vaccinia expression vectors,
rather than after the standard overnight incubation, only
the vac-ss2 env infected cells were recognized by this
clone. The recognition of these cells by clone A42.46 was
dependent on de novo protein synthesis, as cells infected
with vaccinia expression vectors in the presence of cyclo-
heximide were not lysed. This result suggests that targeting
of the env protein for expression in the cytoplasm results in
more rapid and/or efficient processing and presentation of
the antigen by the class I pathway.
Effect of Cytoplasmic Targeting on the Generation of an env-
specific CTL Response In Vivo. To determine whether the
Figure 1. Lysis of targets expressing wt or ss2 env protein by the env-
specific CD81 CTL clone A42.46. Autologous B-LCL were infected with
the indicated vaccinia expression vectors 2 h before assay (diamonds) or were
infected for 2 h and then incubated overnight at 378C before assay
(squares). Infected cells were then used as targets for the env-specific CD81
CTL clone A42.46 in a standard 51Cr release assay at an E/T ratio of 10:1.
One set of targets was infected in the presence of 0.1 mM cycloheximide
(CHX, circles). The experiment was repeated three times with similar re-
sults. Data from a representative experiment are shown.913 Tobery and Siliciano
cytoplasmic targeting of the env protein would result in
enhanced generation of de novo CTL responses in vivo,
BALB/c mice were immunized with the control vaccinia
vector, vac-ss2 env, or with vac-env as described in Mate-
rials and Methods. Splenocytes from immunized mice were
cultured in vitro in the presence or absence of a peptide
representing an immunodominant H-2 Ld–restricted epi-
tope within the env protein, RGPGRAFVTI (49). As seen
in Fig. 2, stimulated splenocytes from mice immunized with
the vac-ss2 env vector were able to recognize and effi-
ciently lyse target cells pulsed with the env peptide. Class II
negative P815 target cells were used in this assay so that
only class I–restricted lysis could be observed. Most impor-
tantly, the lysis by CTLs from mice immunized with vac-
ss2 env was much greater than the lysis mediated by stimu-
lated splenocytes from mice immunized with the vac-env
vector. Splenocytes from mice immunized with a control
vaccinia vector did not lyse targets presenting the relevant
env epitope. When mice were immunized with a higher dose
(108 PFU) of recombinant vaccinia vectors, the immune
response to both constructs was blunted (data not shown).
However, this dose exceeds the standard dose for immuni-
zation with vaccinia virus, and the diminished immune re-
sponse is most likely a result of other secondary effects.
Taken together, these results suggest that targeting the env
protein for translation on free ribosomes in the cytoplasm,
rather than for co-translational translocation into the endo-
plasmic reticulum, results in more rapid and efficient pro-
cessing for presentation to class I–restricted T cells and the
more efficient stimulation of de novo CTL responses in
vivo.
Effect of Cytoplasmic Targeting on CTL Precursor Frequency.
To determine whether the increased CTL response ob-
served in mice immunized with recombinant vaccinia ex-
pressing the cytoplasmic ss2 env reflects a quantitative in-
crease in the number of env-specific CTL precursors in those
mice, we assayed the env-specific CTL precursor frequency
in mice immunized with either vac control, vac-env, or
vac-ss2 env. As shown in Fig. 3, the precursor frequency
of CTLs specific for the P18 env peptide was approxi-
mately fourfold greater in mice immunized with vac-ss2 env
(1/69,618) compared to that observed in mice immunized
Figure 2. Enhanced induction of env-specific CTLs by immunization
with vac ss2 env. BALB/c mice were immunized with 107 PFU of vac
control, vac-env, or vac-ss2 env. Splenocytes from immunized mice were
stimulated for 5 d in IL-2 containing media in the presence of the H-2Ld–
restricted env peptide (RGPGGRAFVTI). Stimulated splenocytes were
then assayed for env-specific CTL activity against P815 cells pulsed with
the H-2Ld–restricted env peptide or media alone. The data shown are
representative of three separate experiments.
Figure 3. Precursor CTL (pCTL) frequency analysis. BALB/c mice
were immunized with 107 PFU vac control, vac-env, or vac-ss2 env. Af-
ter 21 d, splenocytes from immunized mice were cultured (48 wells/titra-
tion) in the presence of 105 naive splenocytes that had been pulsed with
the H-2Ld–restricted env peptide for 2 h and then irradiated for 7 d. Cul-
ture media contained IL-2, T cell growth factor (from Con A–stimulated
rat splenocytes), and methyl-a-d-mannopyranoside. Each well was then
split into two equal parts and assayed for env-specific CTL activity against
P815 targets pulsed with the H-2Ld–restricted env peptide or with media
for 2 h. Positive wells were scored as .3 standard deviations above the
percent specific lysis without effectors. The fraction of negative wells is
plotted on a log scale versus cell number/well and from this line the
pCTL frequency was determined (see Materials and Methods).914 Targeted Degradation of Antigens Enhances the Induction of CTLs
with vac-env (1/267,980). The frequency of env-specific
CTL precursors in mice immunized with vac control was
1/1,154,338. Thus, the enhanced CTL response that is seen
in mice immunized with vac-ss2 env after in vitro stimula-
tion of splenocytes correlates with a fourfold increase in
precursor CTL frequency in these mice relative to mice
that were immunized with vac-env.
Effect of Cytoplasmic Targeting on the Induction of a Primary
CTL Response. Both the analysis of bulk env-specific CTL
responses in stimulated cultures of splenocytes from immu-
nized mice and the analysis of env-specific precursor CTL
frequency involve a secondary antigen-specific stimulation
in vitro. To determine whether the cytoplasmic targeting
of env affects the generation of a primary CTL response in
vivo, we assessed the ability of splenocytes from immu-
nized mice to lyse peptide-pulsed target cells without ear-
lier stimulation in vitro. In the experiment shown in Fig. 4,
when BALB/c mice were immunized with vac-ss2 env, a
vigorous env-specific primary CTL response was detected.
In the same experiment, mice immunized with vac-env
yielded a detectable, but reduced env-specific primary CTL
response, whereas mice that were immunized with the con-
trol vaccinia vector showed no env-specific primary CTL
activity. In other experiments, the levels of primary CTL
activity were much lower, consistent with the general find-
ing that detection of virus-specific CTL usually requires an
in vitro restimulation. Nevertheless, the vac-ss2 env con-
struct was consistently superior to vac-env. These results
indicate that the enhanced CTL responses to vac-ss2 env
detected in bulk culture and limiting dilution studies reflect
enhanced stimulation of de novo CTL responses in vivo by
this degradation targeted construct.
Targeting of the HIV-1 nef Protein for Rapid Cytoplasmic
Degradation. The env protein was targeted for enhanced
class I processing by intentionally inducing the mislocaliza-
tion of the protein to the cytoplasm. To enhance the class I
processing of proteins that are normally localized to the cy-
toplasm, we made use of the N-end rule that states that the
identity of the NH2-terminal residue of a protein deter-
mines its half-life (44). We generated fusion protein con-
structs in which the Ub coding sequence was fused to the
codon for the NH2-terminal residue of the HIV-1 nef pro-
tein. Constructs with a stabilizing Met residue (UbMNef)
or a destabilizing Arg residue (UbRNef) at the NH2-termi-
nus of the nef coding sequence were compared. Prelimi-
nary Western blot analysis established that the steady state
level of the nef protein in cells expressing the UbRNef
construct was much lower than the steady state level of nef
in cells expressing the UbMNef or the wt nef, suggesting
that the UbRNef construct is subject to rapid degradation
(data not shown). The synthesis and degradation rates of the
Ub-Nef fusion proteins as well as wt nef were investigated
in pulse chase experiments, as described in the Materials
and Methods section. Fig. 5 shows that in cells infected
with a vaccinia vector carrying the wt nef gene (vVnef),
the nef protein was stable, with a slow rate of degradation
(t1/2 z10 h). In cells infected with a vaccinia vector carry-
ing the Ub-Met-nef fusion construct (vVUbMNef), nef was
again slowly degraded. A band at the expected relative mo-
lecular mass of a Ub-nef fusion protein, 35 kD, was not
observed, indicating the rapid cleavage at the COOH ter-
minus of Ub by the endogenous Ub hydrolases. The result-
Figure 4. Enhanced stimulation of primary env-specific CTL response
by immunization with vac-ss2 env. BALB/c mice were immunized with
107 PFU vac control, vac-env, or vac-ss2 env. After 6 d, splenocytes were
isolated and assayed for direct CTL activity against peptide-pulsed (filled)
or media-pulsed (open) P815 cells.
Figure 5. Pulse-chase analysis and immunoprecipitation of nef. P815 cells
infected with vaccinia vectors expressing b-gal (lane 1), nef (lanes 2–5),
UbMNef (lanes 6–9), and UbRNef (lanes 10–13) were pulse labeled with
35S-Met and 35S-Cys for 30 min and then chased with an excess of unla-
beled Met and Cys for 0 min (lanes 1, 2, 6, 10), 15 min (lanes 3, 7, 11),
60 min (lanes 4, 8, 12) or 240 min (lanes 5, 9, 13), followed by extrac-
tion, immunoprecipitation, and electrophoretic analysis of nef and MHC
class I expression (see Materials and Methods).915 Tobery and Siliciano
ing nef band derived from the UbMNef construct had a t1/2
slightly less than 10 h. In cells infected with a vaccinia vec-
tor carrying the Ub-Arg-nef fusion construct (vVUbR-
Nef), the fusion construct was again rapidly cleaved to give
Ub and the nef protein, in this case with an Arg residue at
the NH2 terminus. The rate of synthesis of this protein was
similar to that of UbMNef, as judged from the intensity of
the 0 min chase time bands. However, the UbRNef con-
struct displayed a rapid rate of degradation (t1/2 5 15 min),
suggesting that the exposed Arg residue at the NH2 termi-
nus of nef does indeed confer instability and rapid degrada-
tion on this protein in mammalian cells.
In Vitro Studies of the Processing of UbRNef. Preliminary
studies demonstrated that B-LCL infected with vVUbRNef,
vVUbMNef, and vVnef were all lysed to comparable ex-
tents by the previously described nef-specific human CTL
clone 4N225 (50). For other nef-specific human CTL clones,
different patterns were observed, with the degradation tar-
geted construct giving preferential lysis in some cases (data
not shown). However, the critical test of this strategy is to
determine whether cells expressing the degradation targeted
construct are better able to stimulate primary and secondary
CTL responses. To determine whether the rapid degrada-
tion of the UbRNef construct permits enhanced stimulation
of secondary human CTL responses, autologous B-LCL in-
fected with recombinant vaccinia vectors expressing either
UbMNef or UbRNef were used to stimulate nef-specific
memory CTLs present in PBMCs obtained from an HIV-1
seropositive donor. Stimulation of PBMCs with large
numbers of either vVUbMNef-infected B-LCL or vVUbR-
Nef-infected B-LCL led to the induction of a nef-specific
secondary CTL response, as seen in Fig. 6. However, the
number of vVUbMNef-infected stimulating cells required
to obtain a positive CTL response was .30-fold higher
than the number of vVUbRNef-infected stimulating cells
required to induce a comparable response. Thus, on a per
cell basis, cells expressing the rapidly degraded UbRNef
construct are .30-fold more effective at stimulating a sec-
ondary CTL response.
Effect of Targeted nef Degradation on the Generation of nef-
specific CTLs In Vivo. To determine whether the target-
ing of nef for Ub-dependent degradation could enhance
the generation of de novo CTL responses in vivo, BALB/c
mice were immunized with vVUbMNef and vVUbRNef
as described in Materials and Methods. As shown in Fig. 7,
a vigorous nef-specific CTL response was seen after stimu-
lation of splenocytes from mice immunized with vVUbR-
Nef by vVnef-infected CT26 cells. This response was de-
tected using the MHC class I1, MHC class II2 cell line,
CT26, indicating that the lysis was class I restricted. In con-
trast, stimulated splenocytes from mice immunized with
vVUbMNef exhibited a detectable, but much reduced nef-
specific CTL response. Despite this difference in nef-spe-
cific CTL activity, splenocytes that were stimulated with
vVnef-infected CT26 cells had statistically indistinguishable
levels of vaccinia-specific CTL activity, as was seen when
vac control–infected CT26 cells were used as targets in the
CTL assay (29, 27, and 21% vaccinia-specific lysis by sple-
nocytes from mice immunized with vac control, vVUbM-
Nef, and vVUbRNef, respectively). When splenocytes
were stimulated with CT26 cells transfected to express nef,
nef-specific CTL activity was detectable in splenocytes from
mice immunized with vVUbRNef and was virtually lost in
splenocytes from mice immunized with vVUbMNef. This
lower level of stimulation is presumably due to the greater
than fivefold lower level of expression of nef in the stably
transfected CT26 cells than in the vVnef infected CT26
cells as seen by Western blot analysis (data not shown). As
Figure 6. Stimulation of secondary nef-specific CTLs by UbMNef and UbRNef constructs. PBMCs were isolated from an HIV-1 seropositive donor
and stimulated in the presence of IL-2 with titrating numbers of vVUbMNef (squares) or vVUbRNef (diamonds) infected, psoralen/UV–treated autolo-
gous B-LCL. Stimulated PBMCs were assayed for nef-specific CTL activity against vVnef infected (filled) or vac control infected (open) autologous B-LCL
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expected, stimulated splenocytes from mice immunized
with a control vaccinia vector failed to recognize and lyse
target cells expressing nef.
To confirm the results obtained with vaccinia vectors,
we used DNA immunization to express the UbMNef and
UbRNef constructs in mice as described in Materials and
Methods, and evaluated the responses induced by this form
of immunization. As shown in Fig. 8, after antigen-specific
stimulation, splenocytes from mice immunized a single
time with an expression plasmid encoding UbRNef were
able to recognize and lyse nef-expressing CT26 target cells
at low E/T ratios. Stimulated splenocytes from mice im-
munized with plasmid encoding UbMNef, wt nef, or with
plasmid alone were unable to recognize and lyse CT26 tar-
get cells expressing nef even at E/T ratios as high as 100:1.
Nef-expressing P815 target cells were also recognized and
lysed by stimulated splenocytes from UbRNef immunized
mice at low E/T ratios. Stimulated splenocytes from mice
immunized with a plasmid expressing UbMNef or wt nef
were also able to recognize and lyse these targets, but only
at high E/T ratios and at reduced levels relative to the cells
from UbRNef immunized mice. Both target cells used in
these experiments are MHC class II2, indicating that the
lysis mediated by CTLs from mice immunized with
pcDNA3UbRNef was MHC class I restricted. In addition,
lysis of nef-expressing targets by antigen simulated spleno-
cytes from immunized mice was completely blocked by anti-
CD8 antibodies (data not shown). Taken together, these
results indicate that when host cells are induced to express
the rapidly degraded UbRNef, either by immunization with
recombinant vaccinia virus vectors or with a DNA expres-
sion plasmid, BALB/c mice mount a strong primary CTL
response against nef. However, when immunized with a
stable form of nef, either UbMNef or wt nef, the CTL re-
sponse against nef that they mount is greatly reduced or
undetectable.
Discussion
In this paper, we describe a vaccine strategy that is de-
signed specifically to induce an enhanced CD81 CTL re-
sponse. This strategy is based on current understanding of
the MHC class I antigen processing pathway. The source of
peptide substrates for the class I pathway is the cytoplasmic
degradation of antigen by the proteasome. By targeting an-
tigens for rapid cytoplasmic degradation mediated by the
proteasome, we have been able to stimulate enhanced
CD81 CTL responses against the antigens.
Using a ss2 form of the HIV-1 env protein, we have shown
that the rapid degradation of env in the cytoplasm results in
the rapid sensitization of cells expressing the ss2 env to lysis
by an env-specific human CD81 CTL clone, as seen by the
ability of targets expressing this protein, but not the wt env,
to be lysed by CTLs shortly after inducing expression of
the env protein. This rapid sensitization is due to the pres-
ence of peptide-loaded MHC class I molecules on the cell’s
surface, indicating that not only is the protein rapidly de-
graded, but that the peptide products of that degradation
do serve as substrate peptides for the class I processing path-
way. This enhanced degradation, and thus enhanced pro-
cessing, also leads to the induction of a more vigorous
CD81 CTL response in vivo as is seen in the greater CTL
activity observed in splenocytes from mice immunized
with the rapidly degraded env as compared to those from
mice immunized with the wt env. This effect is observed
both in secondary CTL responses in which splenocytes are
stimulated before being assayed for CTL activity and in pri-
mary CTL assays in which splenocytes received no prior in
vitro stimulation. Furthermore, immunization of mice with
the ss2 env results in a quantitative increase in the induction of
memory CTL of almost fourfold relative to immunization
with the wt env. These results are consistent with previous
mechanistic studies showing that for some TAP-dependent
epitopes in the extracellular domain of the env protein,
processing for class I restricted recognition involves degra-
dation of a nonglycosylated form of the protein which pre-
sumably arises by failure of a small fraction of the newly
synthesized env protein to engage the translocation appara-
tus, resulting in mislocalization to the cytoplasm (47). These
findings are also consistent with those of Townsend et al.
(45) who showed that influenza HA protein that lacked a signal
sequence was efficiently processed for presentation to HA-
specific CTLs. It was further observed that deletion of the
HA signal sequence overcame an antigen processing defect
Figure 7. Enhanced induction of primary nef-specific CTLs by immu-
nization with vVUbRNef. BALB/c mice were immunized with 107 PFU
of vac control (open), vVUbMNef (stippled), or vVUbRNef (filled). Sple-
nocytes from immunized mice were stimulated for 5 d in the presence of
IL-2 with either CT26nef transfectants treated with mitomycin C or with
CT26 cells which had been infected with vVnef and then treated with
psoralen/UV light to inactivate vaccinia virus. The ratio of responders to
stimulators was 50:1. Stimulated splenocytes were then assayed for nef-
specific CTL activity against vVnef-infected CT26 cells or vac control–
infected CT26 cells. The percentage nef-specific lysis reported is the per-
centage specific lysis of vVnef-infected targets 2 the percentage specific
lysis of vac control–infected targets. The data shown are from a single ex-
periment which is representative of three experiments conducted with
similar results. 
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observed late in the course of vaccinia infection (42). Our
results extend previous studies showing that the rapid cyto-
plasmic degradation of ss
 
2
 
 env protein enables enhanced
stimulation of both primary and secondary env-specific
CTL responses in vivo.
Townsend et al. also showed that the same defect in an-
tigen processing observed late in vaccinia infection could
be overcome by generating degradation targeted forms of
the influenza nucleoprotein. The nature of the defect was
not elucidated, but may be related to the shutoff of host pro-
tein synthesis by vaccinia. These investigators showed that
a rapidly degraded form of influenza NP expressed by a late
vaccinia promoter was efficiently processed and presented
to NP-specific CTLs, whereas a stable NP was not pre-
sented to those CTLs (42). We have expanded upon that
work by investigating the use of these Ub fusion proteins in
the context of a fully competent antigen processing path-
way. Rather than attempting to rescue the defective pro-
cessing of an Ag, we attempted to enhance the processing
of targeted forms of the antigen relative to the wild-type
forms of the antigen to enhance the induction of primary
and secondary CTL responses against that antigen. Expres-
sion of nef as a Ub-nef fusion protein in which the NH
 
2
 
-
terminal residue of nef was mutated to Arg (UbRNef) con-
ferred rapid degradation to nef. When this construct was
used to stimulate a secondary CTL response, it was 
 
.
 
1 log
more effective than the stable UbMNef at stimulating nef-
specific memory CTL from an HIV-1 infected donor. This
result could have implications for the development of ther-
apeutic vaccines that stimulate memory T cells as well as
naive T cells. In a prophylactic vaccine setting, however, it
is the stimulation of naive T cells, not memory T cells, that
is important. When the UbRNef construct was used to im-
munize naive mice, either in the form of a recombinant
vaccinia vector or a naked DNA expression vector, the
stimulated splenocytes from immunized mice were able to
recognize and lyse target cells expressing the wt nef protein.
Splenocytes from the UbMNef immunized mice, however,
were less able to recognize and lyse these targets. Thus, in
addition to the secondary stimulation of memory CTLs, the
rapidly degraded UbRNef construct is also able to stimu-
late the primary response of naive CTLs in vivo with much
greater efficacy than does the stable UbMNef construct.
In a recent report by Goth et al. (51), it was shown that
targeting OVA for rapid degradation via the generation of
Ub fusion proteins did not result in improved recognition
of cells expressing this construct by a T cell clone. This
suggests that rapid degradation may not lead to enhanced
recognition by all T cell clones, at least as far as can be de-
termined in in vitro assays. Using a panel of human nef-
specific clones, we have observed that whereas some clones
were able to recognize cells expressing the UbRNef con-
struct more efficiently than cells expressing wt nef, other
clones showed equivalent lysis of the targets. Thus, rapid
degradation does not necessarily lead to enhanced presenta-
tion of all CTL epitopes. Because of this variation in recog-
nition that occurs on a clonal level, it is important to examine
the overall effects of targeting antigens for rapid degrada-
tion on the induction of polyclonal CTL responses. In ad-
dition, from the point of view of vaccine development, the
critical question is whether degradation targeted constructs
show enhanced immunogenicity in vivo. We provide here
direct evidence that this is the case for two antigens, HIV-1
env and nef.
Figure 8. Enhanced induc-
tion of nef-specific CTLs by im-
munization with DNA expres-
sion vectors encoding UbRNef.
BALB/c mice were immunized
once with 4 3 50 mg pcDNA3
(open), pcDNA3nef (cross
hatched), pcDNA3UbMNef (stip-
pled), or pcDNA3UbRNef
(filled). Splenocytes from immu-
nized mice were stimulated with
psoralen/UV–treated, vVnef-
infected CT26 cells at a ratio of
50 responders/stimulator cell for
5 d in the presence of IL-2.
Stimulated splenocytes were as-
sayed for nef-specific CTL activ-
ity against CT26 cells infected
with vVnef or with vac control or
against P815 cells infected with
vVnef or vac control at an E/T
ratio of 10:1 or 100:1. The data
shown are from one experiment.
The experiment was repeated a
total of four times, with similar
results.
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Schwartz et al. have recently demonstrated that expres-
sion of the HIV-1 nef protein induces the downregulation
of cell surface MHC class I expression (52). The authors
suggest that this would result in the diminished ability of
cells expressing nef to present peptide epitopes to CD81
CTLs. It is possible that expression of a form of the nef
protein that is targeted for rapid degradation would not
show this effect on MHC class I, and thus cells expressing
this protein would not have diminished abilities to present
peptide epitopes to CTLs. It is unlikely that this effect is re-
sponsible for the enhanced immunogenicity of the vVUbR-
Nef construct, since the ability to stimulate vaccinia-spe-
cific CTLs is unaffected by the degradation rate of nef.
Mice immunized with vaccinia expressing wt nef have in-
distinguishable vac-specific CTLs from mice immunized with
vaccinia expressing rapidly degraded nef. Furthermore, the
numerous studies of the nef-specific CTL response, in both
natural infection with HIV-1 and in animal studies cited
suggest that cells expressing nef are able to efficiently pro-
cess and present nef-derived peptide epitopes to CD81 CTLs.
Whereas the majority of early HIV-1 vaccine efforts fo-
cused on eliciting an immune response against HIV-1 env,
particularly a neutralizing Ab response, the results from
these studies have been disappointing. One of the major
obstacles to these approaches has been the wide genetic
variability of env observed across strains of HIV-1. There-
fore, vaccine strategies targeted against other HIV-1 anti-
gens are now being actively pursued. Since these other
antigens (i.e., gag, pol, and nef) are not present on the sur-
face of the virion or of infected cells, the antibody response
against these antigens is essentially irrelevant. However, these
antigens do represent excellent targets for CD81 CTLs. In-
deed, it has been demonstrated in the simian immunodefi-
ciency virus (SIV) model that vaccine-induced nef-specific
CTLs are able to suppress the early replication of an SIV
challenge in rhesus macaques (9). Also in the SIV model,
it was observed that nef-specific precursor CTLs were de-
tectable within days of acute infection of rhesus macaques
with SIV (12). For HIV-1, nef-specific CTL activity has
been  observed in HIV-uninfected children of HIV-infected
mothers (53, 54). Finally, in HIV-uninfected heterosexual
contacts of HIV-infected patients, nef-specific CTLs are
observed at a much higher frequency than CTLs specific
for other HIV antigens (18). Taken together, these data
suggest that nef-specific CTLs may play a very important
role in the clearance of HIV, particularly immediately after
acute infection, and that this nef-specific CTL response
may be capable of mediating clearance of the virus. There-
fore, augmenting these very important nef-specific CTL
responses by targeting the antigen for rapid cytoplasmic
degradation represents a very attractive strategy for vaccina-
tion against HIV.
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